A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma
Public ClinicalTrials.gov record NCT00304525. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II, Open-label, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265)Administered Orally to Patients With Locally Advanced or Metastatic Melanoma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety profile, pharmacokinetics, pharmacodynamics and maximum tolerated dose of RAF265 in patients with locally advanced and metastatic melanoma. Phase II portion of study (dose expansion) has been cancelled with Amendment 7 as of Dec 2011.
Study identification
- NCT ID
- NCT00304525
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2006 (Type not available)
- Primary completion
- Nov 2013 (Actual)
- Completion
- Nov 2013 (Actual)
- Last update posted
- Dec 19, 2020
2006 – 2013
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Univ.ofColoradoCancerCenter | Aurora | Colorado | 80045 | — |
| Georgia Regents University Cancer Clinical Research Unit | Augusta | Georgia | 30912 | — |
| Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology | Baltimore | Maryland | 21231 | — |
| Massachusetts General Hospital Dept of Cancer for Melanoma | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute DFCI | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center Dept.ofBethIsraelDeaconess(3) | Boston | Massachusetts | 02215 | — |
| University of Pennsylvania Health System Dept of Hospital of UnivofPenn | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Cancer Institute Dept of Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Vanderbilt University Medical Center Dept. of Cancer Center | Nashville | Tennessee | 37232 | — |
| University of Texas/MD Anderson Cancer Center Onc. Dept, | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00304525, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2020 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00304525 live on ClinicalTrials.gov.